Clinical Research Directory
Browse clinical research sites, groups, and studies.
Intensive Cancer Screening After Cryptogenic Stroke
Sponsor: Ottawa Hospital Research Institute
Summary
The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET/CT (F-fluorodeoxyglucose positron emission/computed tomography) in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke.
Official title: Intensive Cancer Screening After Cryptogenic Stroke (INCOGNITO) Pilot Randomized Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
45
Start Date
2023-09-01
Completion Date
2027-01
Last Updated
2025-07-31
Healthy Volunteers
No
Conditions
Interventions
FDG PET/CT
F-fluorodeoxyglucose positron emission/computed tomography
Usual Care
Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care
Locations (1)
The Ottawa Hospital
Ottawa, Ontario, Canada